Previous 10 | Next 10 |
FLORHAM PARK, N.J., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its previously a...
Biotech Penny Stocks To Watch With Recent Updates It’s funny to think that 2020 is almost over yet penny stocks remain a major focus for traders right now. One of the main reasons for this has been the unrelenting focus on volatility. Believe it or not, I think 2020 was p...
Gainers: Jaguar Health (JAGX) +191%.Ocugen (OCGN) +177%.Acasti Pharma (ACST) +88%.Scopus BioPharma (SCPS) +50%.Foresight Autonomous Holdings (FRSX) +35%.Onconova Therapeutics (ONTX) +32%.Evogene (EVGN) +31%.Energous Corporation (WATT) +29%.VivoPower International (VVPR) +26%.Phoenix New Media...
Gainers: Ocugen (OCGN) +263%, Jaguar Health (JAGX) +108%, Acasti Pharma (ACST) +61%, Scopus BioPharma (SCPS) +43%, Ekso Bionics Holdings (EKSO) +21%.Losers: Cellectar Biosciences (CLRB) -31%, CRH Medical (CRHM) -23%, CNS Pharmaceuticals (...
Cellectar Biosciences (CLRB) prices previously announced underwritten public offering of its common stock for gross proceeds of ~$24.5M at a public offering price of $1.35 per share.In a separate concurrent private placement transaction led by healthcare-focused institutional investors, compa...
FLORHAM PARK, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of its previously a...
Cellectar Biosciences (CLRB) intends to offer and sell shares of its common stock in a public offering.Actual size, price or terms of the offering are not yet determined. Concurrently, the Company expects to sell common stock and convertible preferred stock at a public offering price, in a pr...
FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it intends to offer and se...
Looking For Biotech Penny Stocks Right Now? One of the most active sets of penny stocks in 2020 has been biotech stocks. Aside from the obvious push from COVID-19 vaccine candidates, companies are utilizing the increased attention to build upon novel treatment pipelines. Evidenced b...
Are Analysts Right About These Penny Stocks? Whether you’re day trading or investing in penny stocks , everyone wants an edge. Some go to extreme lengths to stay 1 step ahead of the retail market. Whether it’s pouring through pages of filings or actually taking a trip ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
17.22%Change Percent:
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...